David Lane

David Lane is a Senior Professor at the Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet. He leads the Marie Arsenian Henriksson Group focusing on neural differentiation strategies for neuroblastoma treatment and tumor biology research. His work is centered on tumor suppressor biology, particularly the p53 protein and its role in cancer mechanisms.

Research interests include biochemistry, cell biology, and molecular mechanisms of cancer, with a focus on p53 regulation, MDM2/MDMX inhibitors, and therapeutic antibody development. He has been honored with election to the U.S. National Academy of Sciences (2022).

Key contributions include studies on p53 stabilization, phase-separated peptide coacervates for drug delivery, and synergistic immunotherapies. His group collaborates on projects involving spider silk-based protein stabilization and high-throughput microfluidic platforms for intracellular delivery.

Recent grants include over 36 million SEK from the Swedish Research Council for MTC department research. He advises on innovations in cancer diagnostics and drug delivery systems, with publications spanning tumor biology, protein chemistry, and translational oncology.